CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint Genentech, an associate of the Roche Group , announced that CLEOPATRA today, a pivotal Phase III research, met its primary endpoint . Related StoriesNew RNA test of blood platelets can be used to detect location of cancerMeat-rich diet plan may increase kidney cancers riskSausages With Antioxidants From Berries TO AVOID CancerNo new safety indicators were observed and adverse occasions were consistent with those seen in previous studies of pertuzumab and Herceptin, either in combination or alone. Data from CLEOPATRA will be submitted for presentation at the next medical meeting.

However, we feel that it is our duty to aid our colleagues in any way we can to greatly help them complete this difficult time. We hope this task will be beneficial to them. After learning about what happened in Tohoku we sensed an obligation to greatly help. Providing free software obviously doesn’t compensate for losing your house, but at least in a few small way we can help the study institutions in the region get back on their feet, stated CEO of CLC bio Japan, David Leangen, and continued, When RIKEN heard about our task and proposed to greatly help, we were grateful, as having RIKEN’s help will allow us to attain a much bigger audience. The licenses CLC bio can be donating, are permanently owned by the agencies that choose to be section of the outreach plan. CLC bio Japan is also providing full support in addition to upgrades for the initial full year, following the licenses are set up.